These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 12751766)

  • 61. New functions for Cox-2 in health and disease: report of "The Third International Workshop on Cox-2", Ka'upelehu, Kona, Hawaii, USA, 30 August to 2 September 1999.
    Wollheim FA
    Arthritis Res; 1999; 1(1):45-9. PubMed ID: 11219386
    [No Abstract]   [Full Text] [Related]  

  • 62. Re-addressing relative selectivities.
    Botting R; Vane J
    Trends Pharmacol Sci; 1997 Sep; 18(9):312-3. PubMed ID: 9345848
    [No Abstract]   [Full Text] [Related]  

  • 63. 24R,25-(OH)(2)D(3) mediates its membrane receptor-dependent effects on protein kinase C and alkaline phosphatase via phospholipase A(2) and cyclooxygenase-1 but not cyclooxygenase-2 in growth plate chondrocytes.
    Schwartz Z; Sylvia VL; Del Toro F; Hardin RR; Dean DD; Boyan BD
    J Cell Physiol; 2000 Mar; 182(3):390-401. PubMed ID: 10653606
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Inhibition of cyclooxygenases reduces complement-induced glomerular epithelial cell injury and proteinuria in passive Heymann nephritis.
    Takano T; Cybulsky AV; Cupples WA; Ajikobi DO; Papillon J; Aoudjit L
    J Pharmacol Exp Ther; 2003 Apr; 305(1):240-9. PubMed ID: 12649375
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Studies of pulmonary prostaglandin biosynthetic and catabolic enzymes as factors in ductus arteriosus patency and closure. Evidence for a shift in products with gestational age.
    Printz MP; Skidgel RA; Friedman WF
    Pediatr Res; 1984 Jan; 18(1):19-24. PubMed ID: 6422431
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor.
    Riendeau D; Percival MD; Boyce S; Brideau C; Charleson S; Cromlish W; Ethier D; Evans J; Falgueyret JP; Ford-Hutchinson AW; Gordon R; Greig G; Gresser M; Guay J; Kargman S; Léger S; Mancini JA; O'Neill G; Ouellet M; Rodger IW; Thérien M; Wang Z; Webb JK; Wong E; Chan CC
    Br J Pharmacol; 1997 May; 121(1):105-17. PubMed ID: 9146894
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Styrylheterocycles as a novel class inhibitor of cyclooxygenase-2-mediated prostaglandin E(2) production.
    Lee SK; Park EJ; Lee E; Min HY; Kim EY; Lee T; Kim S
    Bioorg Med Chem Lett; 2004 May; 14(9):2105-8. PubMed ID: 15080988
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Do inhibitors of cyclooxygenase-2 impair bone healing?
    Einhorn TA
    J Bone Miner Res; 2002 Jun; 17(6):977-8. PubMed ID: 12054172
    [No Abstract]   [Full Text] [Related]  

  • 69. The cyclooxygenase isoforms: structural insights into the conversion of arachidonic acid to prostaglandins.
    Garavito RM; DeWitt DL
    Biochim Biophys Acta; 1999 Nov; 1441(2-3):278-87. PubMed ID: 10570255
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Mechanism of cyclooxygenase-2 inhibition by indanone derivatives.
    Klein T; Nüsing RM
    Adv Exp Med Biol; 1997; 407():503-7. PubMed ID: 9321998
    [No Abstract]   [Full Text] [Related]  

  • 71. Effect of constitutive- and inducible-cyclooxygenase in the carbachol-induced pituitary-adrenocortical response during social stress.
    Bugajski J; Gadek-Michalska A; Bugajski AJ
    J Physiol Pharmacol; 2002 Sep; 53(3):453-62. PubMed ID: 12369741
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [Thinking about the specific cyclooxygenase-2 inhibitors since its recommendation].
    Shi G
    Zhonghua Nei Ke Za Zhi; 2001 Sep; 40(9):579-80. PubMed ID: 11758234
    [No Abstract]   [Full Text] [Related]  

  • 73. Characteristics of COX2 inhibitors questioned.
    Petit-Zeman S
    Nat Rev Drug Discov; 2004 Sep; 3(9):726-7. PubMed ID: 15368654
    [No Abstract]   [Full Text] [Related]  

  • 74. Cyclo-oxygenase-2 and renal function.
    Krämer BK
    Nephrol Dial Transplant; 2001 Jan; 16(1):180-3. PubMed ID: 11209021
    [No Abstract]   [Full Text] [Related]  

  • 75. Comparison of the antipyretic actions of indomethacin and L-745,337, a selective cyclooxygenase-2 inhibitor, in endotoxin-treated prepubertal pigs.
    Parrott RF; Vellucci SV
    Gen Pharmacol; 1998 Jan; 30(1):65-9. PubMed ID: 9457483
    [TBL] [Abstract][Full Text] [Related]  

  • 76. 1,2-Diaryl-1-ethanone and pyrazolo [4,3-c] quinoline-4-one as novel selective cyclooxygenase-2 inhibitors.
    Baruah B; Dasu K; Vaitilingam B; Vanguri A; Rao Casturi S; Rao Yeleswarapu K
    Bioorg Med Chem Lett; 2004 Jan; 14(2):445-8. PubMed ID: 14698178
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Chronic in utero cyclooxygenase inhibition alters PGE2-regulated ductus arteriosus contractile pathways and prevents postnatal closure.
    Reese J; Waleh N; Poole SD; Brown N; Roman C; Clyman RI
    Pediatr Res; 2009 Aug; 66(2):155-61. PubMed ID: 19390487
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Failure of ductus arteriosus closure and remodeling in neonatal mice deficient in cyclooxygenase-1 and cyclooxygenase-2.
    Loftin CD; Trivedi DB; Tiano HF; Clark JA; Lee CA; Epstein JA; Morham SG; Breyer MD; Nguyen M; Hawkins BM; Goulet JL; Smithies O; Koller BH; Langenbach R
    Proc Natl Acad Sci U S A; 2001 Jan; 98(3):1059-64. PubMed ID: 11158594
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Selective COX-2 inhibition is associated with decreased mucosal damage induced by acid and pepsin in rabbit esophagitis.
    Lanas A; Jiménez P; Ferrández A; Escartín A; Arenas J; Esteva F; Ortego J
    Inflammation; 2003 Feb; 27(1):21-9. PubMed ID: 12772774
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Cox-2 inhibitory effects of naturally occurring and modified fatty acids.
    Ringbom T; Huss U; Stenholm A; Flock S; Skattebøl L; Perera P; Bohlin L
    J Nat Prod; 2001 Jun; 64(6):745-9. PubMed ID: 11421736
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.